Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Rhinovirus 16 (HRV-16) is a specific serotype of human rhinovirus belonging to the genus *Enterovirus* in the family *Picornaviridae*. It is a small (about 30 nm), non-enveloped virus with an icosahedral capsid and a single-stranded positive-sense RNA genome. HRV-16 primarily infects nasal epithelial cells in the upper respiratory tract and is commonly used as a model organism in respiratory and infectious disease research[1][3][4]. The virus causes mild symptoms such as sore throat, cough, runny nose, and nasal congestion but can exacerbate pre-existing respiratory conditions like asthma or chronic obstructive pulmonary disease (COPD)[2][3][5]. In laboratory settings, it is propagated in H1HeLa cells. There are currently no FDA-approved vaccines or antiviral treatments specifically for rhinoviruses[3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on rhinovirus 16.